


BioIVT acquires Keystone Biologicals

08 August 2019 | News

This transaction increases BioIVT's portfolio of disease-state plasma, sera and controls, and enhances its ability to support the in vitro diagnostic market



BioIVT, a global leading provider of research models and services for drug and diagnostic development has acquired Keystone Biologicals, Inc., a global supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT's disease-state portfolio both by volume and product range.

"With the addition of Keystone Biologicals, BioIVT broadens its product offerings and better supports clients in the *in vitro* diagnostic (IVD) market," said BioIVT Chief Executive Officer Jeffrey Gatz. "This acquisition furthers our mission of becoming the partner of choice for both biopharmaceutical and diagnostic clients."

Keystone Biologicals provides a broad range of autoimmune, serology and virology, immunology, and tumor marker research samples. Its antibody positive cohorts include donors with infectious diseases such as hepatitis, herpes, syphilis and toxoplasmosis, and autoimmune diseases such as rheumatoid factor and systemic lupus. It also offers liquid-stable controls, standards and calibrators for use with stock or custom-produced diagnostic kits.

In addition, Keystone Biologicals' in-house laboratory enables it to characterize raw material using a variety of testing formats including the client's own test kits. By using clients' own assays, Keystone Biologicals can help ensure that clients do not spend time and money evaluating material that does not meet their study requirements.

Financial details about this transaction were not disclosed.